Efficacy of pH-Sensitive Nanomedicines in Tumors with Different c-MYC Expression Depends on the Intratumoral Activation Profile
出版年份 2021 全文链接
标题
Efficacy of pH-Sensitive Nanomedicines in Tumors with Different c-MYC Expression Depends on the Intratumoral Activation Profile
作者
关键词
-
出版物
ACS Nano
Volume -, Issue -, Pages -
出版商
American Chemical Society (ACS)
发表日期
2021-02-25
DOI
10.1021/acsnano.1c00364
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Target gene-independent functions of MYC oncoproteins
- (2020) Apoorva Baluapuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo
- (2020) Valentina Maggisano et al. Cancers
- A Phase 1b Dose-Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma
- (2020) Sant P Chawla et al. CLINICAL CANCER RESEARCH
- Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- (2020) V. Moreno et al. ANNALS OF ONCOLOGY
- Supramolecularly enabled pH- triggered drug action at tumor microenvironment potentiates nanomedicine efficacy against glioblastoma
- (2020) Sabina Quader et al. BIOMATERIALS
- Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
- (2019) Vivian Chua et al. EMBO Molecular Medicine
- Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for “on-demand” drug delivery
- (2019) Ying Qu et al. JOURNAL OF CONTROLLED RELEASE
- Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151 and IBET-762 in OSCC cells
- (2019) Federica Baldan et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer
- (2019) Mohamed Elbadawy et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1
- (2019) Hairui Wang et al. NANO LETTERS
- Bromodomains: a new target class for drug development
- (2019) Andrea G. Cochran et al. NATURE REVIEWS DRUG DISCOVERY
- Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
- (2019) Benjamin Bian et al. Frontiers in Oncology
- Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
- (2019) Brittany L. Allen-Petersen et al. BIODRUGS
- JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer
- (2019) Ying Tian et al. ACS Applied Materials & Interfaces
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
- (2019) Huiying Han et al. CANCER CELL
- BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma
- (2019) Miao Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Heterogeneity of Myc expression in breast cancer exposes pharmacological vulnerabilities revealed through executable mechanistic modeling
- (2019) Peter Kreuzaler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
- (2018) K A Blum et al. ANNALS OF ONCOLOGY
- Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma
- (2018) Jingyuan Wang et al. CANCER LETTERS
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MYC in multiple myeloma
- (2018) K. K. Jovanović et al. LEUKEMIA
- Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
- (2018) Fred C. Lam et al. Nature Communications
- Progress and challenges towards targeted delivery of cancer therapeutics
- (2018) Daniel Rosenblum et al. Nature Communications
- The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
- (2018) Bei Zhao et al. MELANOMA RESEARCH
- Systems analysis of intracellular pH vulnerabilities for cancer therapy
- (2018) Erez Persi et al. Nature Communications
- Brd4’s Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1
- (2018) Tao Wu et al. Cell Reports
- A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors
- (2017) Hirofumi Mukai et al. INVESTIGATIONAL NEW DRUGS
- cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells
- (2017) Kazuki Miyano et al. JOURNAL OF CONTROLLED RELEASE
- Patients with high c-MYC-expressing squamous cell carcinomas of the tongue show better survival than those with low- and medium-expressing tumours
- (2017) Klas Strindlund et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family
- (2017) Chunyan Cheng et al. PHYSICAL CHEMISTRY CHEMICAL PHYSICS
- Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC
- (2017) Kiyotoshi Satoh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer
- (2017) Nidhi Gupta et al. Oncotarget
- Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer
- (2017) Montserrat Pérez-Salvia et al. Oncotarget
- pH-Responsive Aerobic Nanoparticles for Effective Photodynamic Therapy
- (2017) Lingyue Shen et al. Theranostics
- Nanomedicines Eradicating Cancer Stem-like Cells in Vivo by pH-Triggered Intracellular Cooperative Action of Loaded Drugs
- (2016) Hiroaki Kinoh et al. ACS Nano
- Stimuli-Responsive Programmed Specific Targeting in Nanomedicine
- (2016) Sheng Wang et al. ACS Nano
- msIQuant – Quantitation Software for Mass Spectrometry Imaging Enabling Fast Access, Visualization, and Analysis of Large Data Sets
- (2016) Patrik Källback et al. ANALYTICAL CHEMISTRY
- Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease
- (2016) Yulia A. Nevzorova et al. JOURNAL OF HEPATOLOGY
- Absolute Quantification of Rifampicin by MALDI Imaging Mass Spectrometry Using Multiple TOF/TOF Events in a Single Laser Shot
- (2016) Boone M. Prentice et al. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
- A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy
- (2016) Peng Mi et al. Nature Nanotechnology
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
- (2016) L L da Motta et al. ONCOGENE
- BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
- (2016) Ballachanda N Devaiah et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells
- (2016) Fuyumi Kato et al. Oncotarget
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- A transistor-like pH nanoprobe for tumour detection and image-guided surgery
- (2016) Tian Zhao et al. Nature Biomedical Engineering
- Small-molecule inhibitors of the Myc oncoprotein
- (2015) Steven Fletcher et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
- (2015) Aijun Shen et al. CANCER RESEARCH
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer
- (2015) Haifeng Qiu et al. Oncotarget
- Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- (2015) Gabor Borbely et al. Oncotarget
- Bundled Assembly of Helical Nanostructures in Polymeric Micelles Loaded with Platinum Drugs Enhancing Therapeutic Efficiency against Pancreatic Tumor
- (2014) Yuki Mochida et al. ACS Nano
- Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
- (2014) Mar Gacias et al. CHEMISTRY & BIOLOGY
- Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
- (2014) S. E. Trabucco et al. CLINICAL CANCER RESEARCH
- Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy
- (2014) S. Quader et al. JOURNAL OF CONTROLLED RELEASE
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis
- (2013) J. R. Doherty et al. CANCER RESEARCH
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
- (2013) P. Bandopadhayay et al. CLINICAL CANCER RESEARCH
- Acidosis Decreases c-Myc Oncogene Expression in Human Lymphoma Cells: A Role for the Proton-Sensing G Protein-Coupled Receptor TDAG8
- (2013) Zhigang Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Stimuli-responsive nanocarriers for drug delivery
- (2013) Simona Mura et al. NATURE MATERIALS
- Small-Molecule Inhibition of BRDT for Male Contraception
- (2012) Martin M. Matzuk et al. CELL
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Contribution of Na+,HCO3−-cotransport to cellular pH control in human breast cancer: A role for the breast cancer susceptibility locus NBCn1 (SLC4A7)
- (2012) Ebbe Boedtkjer et al. INTERNATIONAL JOURNAL OF CANCER
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- 13C-Pyruvate Imaging Reveals Alterations in Glycolysis that Precede c-Myc-Induced Tumor Formation and Regression
- (2011) Simon Hu et al. Cell Metabolism
- Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging
- (2011) György Marko-Varga et al. Journal of Proteomics
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Modelling Myc inhibition as a cancer therapy
- (2008) Laura Soucek et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search